Bob Proulx, Imagion’s CEO, and Dr. Yalia Jayalakshmi, Chief Development Officer discussed the latest positive independent review of our MagSense® HER2 imaging agent including what this means for Imagion Biosystems; how this accelerates our path to market; an update on the future of our technology; and fielded questions from attendees in a Q&A session.
Izaac Ronay from The Stock Network sat down with Imagion Biosystems’ Ward Detwiler to discuss the new written series, “10 Things to Know About MagSense®”, which
Bringing molecular specificity to MRI could change the way cancer is diagnosed. We’re proud of the first-of-its-kind technology behind MagSense®, but breakthrough technology alone does